Table 1.
Demographics and study drug dosing for adherent subjects with gestational diabetes and gestational age-matched healthy pregnant subjects who completed the study
| All GDM | COMBO | GLY | MET | HP | |
|---|---|---|---|---|---|
| n | 89 | 32 | 32 | 25 | 28 |
| Race/Ethnicity: | |||||
| White (%) | 81.2 | 78.1 | 80.0 | 82.1 | |
| Black (%) | 9.4 | 21.9 | 16.0 | 17.9 | |
| Hispanic (%) | 34.4 | 40.6 | 36.0 | 32.1 | |
| Asian (%) | 5.6 | 0 | 4.0 | 0 | |
| Native American (%) | 2.8 | 0 | 0 | 0 | |
| Age SD1 (years) | 30 ± 5 (19 to 42) | 29 ± 4 (19 to 37) | 30 ± 6 (20 to 42) | 31 ± 4 (22 to 39) | 25 ± 5 (18 to 38) (p<0.001)* |
| Height SD1 (cm) | 162 ± 6 (147 to 179) | 162 ± 7 (153 to 175) | 161 ± 6 (147 to 173) | 162 ± 6 (147 to 179) | 162 ± 8 (147 to 178) |
| Body weight SD1 (kg) | 90 ± 20 (60 to 200) | 100 ± 20 (60 to 200) | 90 ± 20 (60 to 200) | 90 ± 10 (70 to 100) | 80 ± 10 (50 to 100) (p<0.001)* |
| BMI Pre-pregnancy (kg/m2) | 33 ± 7 (20 to 55) | 34 ± 8 (22 to 55) | 33 ± 6 (20 to 53) | 31 ± 6 (21 to 43) | 27 ± 5 (20 to 40) (p<0.001)* |
| GA, SD1 (weeks) | 30 ± 2 (19 to 33) | 30 ± 3 (19 to 33) | 30 ± 2 (24 to 33) | 31 ± 2 (20 to 33) | 30 ± 1 (28 to 33) |
| GA, SD2 (weeks) | 35 ± 2 (26 to 39) | 35 ± 3 (26 to 38) | 36 ± 2 (32 to 39) | 35 ± 1 (32 to 38) | 36 ± 1 (34 to 38) |
| Glyburide dose SD2 (mg/day) | 8 ± 6 (1 to 30) | 6 ± 4 (1 to 20) | 10 ± 6 (2 to 30) | NA | NA |
| Metformin dose SD2 (mg/day) | 1,300 ± 500 (1,000 to 2,600) | 1,200 ± 500 (1,000 to 2,600) | NA | 1,400 ± 500 (1,000 to 2,000) | NA |
BMI = Body Mass Index, COMBO = glyburide/metformin combination, GA = gestational age, GDM = gestational diabetes mellitus, HP = Healthy pregnant subjects, GLY = glyburide monotherapy; MET = metformin monotherapy, COMBO = glyburide plus metformin combination therapy, SD1 = study day 1, SD2 = study day 2, * = significantly different than all GDM subjects, results reported as mean ± SD (range).